Quanterix Co. (NASDAQ:QTRX) Stock Position Lowered by Farallon Capital Management LLC

Farallon Capital Management LLC decreased its position in Quanterix Co. (NASDAQ:QTRX) by 83.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 80,000 shares of the company’s stock after selling 391,000 shares during the period. Farallon Capital Management LLC owned about 0.21% of Quanterix worth $1,057,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC boosted its position in shares of Quanterix by 22.9% in the first quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock worth $41,398,000 after buying an additional 326,876 shares during the period. Superstring Capital Management LP purchased a new position in Quanterix during the 4th quarter valued at about $1,962,000. Williams Jones Wealth Management LLC. acquired a new position in shares of Quanterix in the 1st quarter valued at about $1,327,000. Easterly Investment Partners LLC lifted its position in shares of Quanterix by 551.1% in the first quarter. Easterly Investment Partners LLC now owns 78,734 shares of the company’s stock worth $1,855,000 after purchasing an additional 66,642 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Quanterix by 15.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 974,111 shares of the company’s stock worth $26,635,000 after purchasing an additional 131,195 shares during the period. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director David R. Walt acquired 47,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average cost of $13.29 per share, with a total value of $624,630.00. Following the acquisition, the director now owns 1,487,342 shares in the company, valued at $19,766,775.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

Analyst Ratings Changes

QTRX has been the topic of several research reports. Scotiabank dropped their price objective on shares of Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research note on Monday, August 12th. The Goldman Sachs Group dropped their price target on shares of Quanterix from $35.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday, July 9th. Finally, TD Cowen cut their price objective on Quanterix from $17.00 to $15.00 and set a “hold” rating for the company in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.80.

Quanterix Trading Down 4.5 %

Shares of NASDAQ:QTRX opened at $13.89 on Tuesday. Quanterix Co. has a 1 year low of $10.50 and a 1 year high of $29.70. The firm has a fifty day moving average price of $13.41 and a 200 day moving average price of $16.18. The stock has a market capitalization of $531.57 million, a PE ratio of -14.47 and a beta of 1.36.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Quanterix had a negative net margin of 30.71% and a negative return on equity of 11.52%. The company had revenue of $34.38 million for the quarter, compared to analyst estimates of $34.19 million. During the same period in the prior year, the company posted ($0.16) EPS. On average, sell-side analysts forecast that Quanterix Co. will post -0.88 earnings per share for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.